<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Exenatide</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Exenatide">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Exenatide</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Exenatide</b>, sold under the brand name <b>Byetta</b> and <b>Bydureon</b> among others, is a medication used to treat diabetes mellitus type 2.<span class="mw-ref" id="cite_ref-AHFS2019_1-0"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It is used together with diet, exercise, and potentially other antidiabetic medication.<span class="mw-ref" id="cite_ref-AHFS2019_1-1"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It is a less preferred treatment option after <a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Metformin" title="Metformin">metformin</a> and sulfonylureas.<span class="mw-ref" id="cite_ref-BNF76_2-0"><a href="#cite_note-BNF76-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is given by injection under the skin within an hour before the first and last meal of the day.<span class="mw-ref" id="cite_ref-AHFS2019_1-2"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> A once-weekly injection version is also available.<span class="mw-ref" id="cite_ref-AHFS2019_1-3"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Exenatide</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Exenatide_sequence.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Exenatide_sequence.svg.png" data-file-width="512" data-file-height="272" data-file-type="drawing" height="117" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td><span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>ɛ</span><span>ɡ</span><span>z</span><span>ˈ</span><span>ɛ</span><span>n</span><span>ə</span><span>t</span><span>aɪ</span><span>d</span></span>/</span><span> </span><span class="nowrap" style="font-size:85%">(<span class="unicode haudio"><span class="fn"><span style="white-space:nowrap;margin-right:.25em;"><figure-inline><img src="../I/m/Loudspeaker.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Loudspeaker.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="11" width="11"></figure-inline></span><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/I/m/En-us-Exenatide.ogg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/I/m/En-us-Exenatide.ogg'" tppabs="https://ptable.com/wiki/compounds/I/m/En-us-Exenatide.ogg" resource="./Media:En-us-Exenatide.ogg" title="En-us-Exenatide.ogg">listen</a></span></span>)</span></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Byetta, Bydureon, Bydureon BCise, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/exenatide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/exenatide.html'" tppabs="https://www.drugs.com/monograph/exenatide.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a605034.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a605034.html'" tppabs="https://medlineplus.gov/druginfo/meds/a605034.html" class="external text external">a605034</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Exenatide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Exenatide'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Exenatide" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Exenatide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Exenatide'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Exenatide" class="external text external">Exenatide</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>C<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Subcutaneous injection</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>A10BJ01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=A10BJ01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=A10BJ01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=A10BJ01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li>
<li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>N/A</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>proteolysis</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>2.4 h</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>renal/proteolysis</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=141732-76-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=141732-76-5'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=141732-76-5" class="external text external">141732-76-5</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/16157882  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/16157882'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/16157882" class="external text external">16157882</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1135  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1135'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1135" class="external text external">1135</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB01276  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB01276'" tppabs="https://www.drugbank.ca/drugs/DB01276" class="external text external">DB01276</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.17314184.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.17314184.html'" tppabs="http://www.chemspider.com/Chemical-Structure.17314184.html" class="external text external">17314184</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=9P1872D4OL  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=9P1872D4OL'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=9P1872D4OL" class="external text external">9P1872D4OL</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D04121  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D04121'" tppabs="https://www.kegg.jp/entry/D04121" class="external text external">D04121</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID9040475  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID9040475'" tppabs="https://comptox.epa.gov/dashboard/DTXSID9040475" class="external text external">DTXSID9040475</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.212.123  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.212.123'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.212.123" class="external text external">100.212.123</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>184</sub><span>H</span><sub>282</sub><span>N</span><sub>50</sub><span>O</span><sub>60</sub><span>S</span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">4<span style="margin-left:.25em;">186</span>.63</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=%5BH%5D%2FN%3DC%28%5CN%29%2FNCCC%5BC%40%40H%5D%28C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28Cc1ccccc1%29C%28%3DO%29N%5BC%40%40H%5D%28%5BC%40%40H%5D%28C%29CC%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28Cc2c%5BnH%5Dc3c2cccc3%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CCCCN%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29NCC%28%3DO%29NCC%28%3DO%29N4CCC%5BC%40H%5D4C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29NCC%28%3DO%29N%5BC%40%40H%5D%28C%29C%28%3DO%29N5CCC%5BC%40H%5D5C%28%3DO%29N6CCC%5BC%40H%5D6C%28%3DO%29N7CCC%5BC%40H%5D7C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%29NC%28%3DO%29%5BC%40H%5D%28C%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28C%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCSC%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29N%29NC%28%3DO%29%5BC%40H%5D%28CCCCN%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28CC%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28CC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29O%29NC%28%3DO%29%5BC%40H%5D%28Cc8ccccc8%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29O%29NC%28%3DO%29CNC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29CNC%28%3DO%29%5BC%40H%5D%28Cc9cnc%5BnH%5D9%29N  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=%5BH%5D%2FN%3DC%28%5CN%29%2FNCCC%5BC%40%40H%5D%28C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28Cc1ccccc1%29C%28%3DO%29N%5BC%40%40H%5D%28%5BC%40%40H%5D%28C%29CC%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28Cc2c%5BnH%5Dc3c2cccc3%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CCCCN%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29NCC%28%3DO%29NCC%28%3DO%29N4CCC%5BC%40H%5D4C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29NCC%28%3DO%29N%5BC%40%40H%5D%28C%29C%28%3DO%29N5CCC%5BC%40H%5D5C%28%3DO%29N6CCC%5BC%40H%5D6C%28%3DO%29N7CCC%5BC%40H%5D7C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%29NC%28%3DO%29%5BC%40H%5D%28C%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28C%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCSC%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29N%29NC%28%3DO%29%5BC%40H%5D%28CCCCN%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28CC%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28CC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29O%29NC%28%3DO%29%5BC%40H%5D%28Cc8ccccc8%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29O%29NC%28%3DO%29CNC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29CNC%28%3DO%29%5BC%40H%5D%28Cc9cnc%5BnH%5D9%29N'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=%5BH%5D%2FN%3DC%28%5CN%29%2FNCCC%5BC%40%40H%5D%28C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28Cc1ccccc1%29C%28%3DO%29N%5BC%40%40H%5D%28%5BC%40%40H%5D%28C%29CC%29C%28%3DO%29N%5BC%40%40H%5D%28CCC%28%3DO%29O%29C%28%3DO%29N%5BC%40%40H%5D%28Cc2c%5BnH%5Dc3c2cccc3%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28C%29C%29C%28%3DO%29N%5BC%40%40H%5D%28CCCCN%29C%28%3DO%29N%5BC%40%40H%5D%28CC%28%3DO%29N%29C%28%3DO%29NCC%28%3DO%29NCC%28%3DO%29N4CCC%5BC%40H%5D4C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29NCC%28%3DO%29N%5BC%40%40H%5D%28C%29C%28%3DO%29N5CCC%5BC%40H%5D5C%28%3DO%29N6CCC%5BC%40H%5D6C%28%3DO%29N7CCC%5BC%40H%5D7C%28%3DO%29N%5BC%40%40H%5D%28CO%29C%28%3DO%29N%29NC%28%3DO%29%5BC%40H%5D%28C%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28C%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CCSC%29NC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29N%29NC%28%3DO%29%5BC%40H%5D%28CCCCN%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28CC%28C%29C%29NC%28%3DO%29%5BC%40H%5D%28CC%28%3DO%29O%29NC%28%3DO%29%5BC%40H%5D%28CO%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29O%29NC%28%3DO%29%5BC%40H%5D%28Cc8ccccc8%29NC%28%3DO%29%5BC%40H%5D%28%5BC%40%40H%5D%28C%29O%29NC%28%3DO%29CNC%28%3DO%29%5BC%40H%5D%28CCC%28%3DO%29O%29NC%28%3DO%29CNC%28%3DO%29%5BC%40H%5D%28Cc9cnc%5BnH%5D9%29N" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">[H]/N=C(\N)/NCCC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc2c[nH]c3c2cccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N4CCC[C@H]4C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N5CCC[C@H]5C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc8ccccc8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](Cc9cnc[nH]9)N</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)227-138(247)82-199-153(264)109(48-54-140(249)250)204-137(246)81-197-152(263)104(187)74-102-78-193-89-201-102/h17-24,34-39,77-78,89-98,104,106-132,146-149,195,235-241H,16,25-33,40-76,79-88,185-187H2,1-15H3,(H2,188,242)(H2,189,243)(H2,190,261)(H,193,201)(H,196,244)(H,197,263)(H,198,265)(H,199,264)(H,200,266)(H,202,245)(H,203,267)(H,204,246)(H,205,276)(H,206,283)(H,207,268)(H,208,272)(H,209,273)(H,210,275)(H,211,271)(H,212,288)(H,213,289)(H,214,270)(H,215,279)(H,216,280)(H,217,277)(H,218,274)(H,219,269)(H,220,284)(H,221,290)(H,222,287)(H,223,285)(H,224,278)(H,225,286)(H,226,291)(H,227,247)(H,228,262)(H,229,281)(H,230,282)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,259,260)(H4,191,192,194)/t94-,95-,96-,97+,98+,104-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,146-,147-,148-,149-/m0/s1<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:HTQBXNHDCUEHJF-XWLPCZSASA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=443485715&page2=Exenatide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=443485715&page2=Exenatide'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=443485715&page2=Exenatide" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Common side effects include low blood sugar, nausea, dizziness, abdominal pain, and pain at the site of injection.<span class="mw-ref" id="cite_ref-AHFS2019_1-4"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Other serious side effects may include medullary thyroid cancer, angioedema, pancreatitis, and kidney injury.<span class="mw-ref" id="cite_ref-AHFS2019_1-5"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Use in pregnancy and breastfeeding is of unclear safety.<span class="mw-ref" id="cite_ref-Preg2019_3-0"><a href="#cite_note-Preg2019-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics.<span class="mw-ref" id="cite_ref-AHFS2019_1-6"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It works by increasing insulin release from the pancreas and decreases excessive <a href="Glucagon.htm" tppabs="https://ptable.com/wiki/compounds/A/Glucagon" title="Glucagon">glucagon</a> release.<span class="mw-ref" id="cite_ref-AHFS2019_1-7"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


<p>Exenatide was approved for medical use in the United States in 2005.<span class="mw-ref" id="cite_ref-AHFS2019_1-8"><a href="#cite_note-AHFS2019-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> A month supply in the United Kingdom costs the NHS about £82 for the daily injectable and £73 for the weekly injectable version as of 2019.<span class="mw-ref" id="cite_ref-BNF76_2-1"><a href="#cite_note-BNF76-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> In the United States the wholesale cost of this amount is about <span style="white-space: nowrap">US$</span>700 and <span style="white-space: nowrap">US$</span>789 respectively.<span class="mw-ref" id="cite_ref-NADAC2019_4-0"><a href="#cite_note-NADAC2019-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> In 2017, it was the 260th most commonly prescribed medication in the United States, with more than one million prescriptions.<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_use">Medical use</h2></summary>
    
<p>Exenatide is used to treat type 2 diabetes mellitus as an add-on to <a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Metformin" title="Metformin">metformin</a>, a biguanide, or a combination of metformin and a sulfonylurea, or  <a href="Thiazolidinedione.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiazolidinediones" title="Thiazolidinediones" class="mw-redirect">thiazolidinediones</a> such as <a href="Pioglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pioglitazone" title="Pioglitazone">pioglitazone</a>.<span class="mw-ref" id="cite_ref-UKByettalabel_7-0"><a href="#cite_note-UKByettalabel-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-UKBydureonlabel_8-0"><a href="#cite_note-UKBydureonlabel-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> It is also being evaluated for use in the treatment of Parkinson's disease.<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>

<p>The medication is injected subcutaneously twice per day using a filled pen-like device (Byetta), or on a weekly basis with either a pen-like device or conventional syringe (Bydureon). The abdomen is a common injection site.<span class="mw-ref" id="cite_ref-UKByettalabel_7-1"><a href="#cite_note-UKByettalabel-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-UKBydureonlabel_8-1"><a href="#cite_note-UKBydureonlabel-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<p>The main side effects of exenatide use are gastrointestinal in nature, including acid or sour stomach, belching, diarrhea, heartburn, indigestion, nausea, and vomiting; exenatide is therefore not meant for people with severe gastrointestinal disease. Other side effects include dizziness, headache, and feeling jittery.<span class="mw-ref" id="cite_ref-drugs.com_10-0"><a href="#cite_note-drugs.com-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> Drug interactions listed on the package insert include delayed or reduced concentrations of <a href="Lovastatin.htm" tppabs="https://ptable.com/wiki/compounds/A/Lovastatin" title="Lovastatin">lovastatin</a>, <a href="Paracetamol.htm" tppabs="https://ptable.com/wiki/compounds/A/Paracetamol" title="Paracetamol">paracetamol</a> (acetaminophen), and <a href="Digoxin.htm" tppabs="https://ptable.com/wiki/compounds/A/Digoxin" title="Digoxin">digoxin</a>, although this has not been proven to alter the effectiveness of these other medications.   </p>
 
<p>In response to postmarketing reports of acute pancreatitis in patients using exenatide, the FDA added a warning to the labeling of Byetta in 2007.<span class="mw-ref" id="cite_ref-fda-1_11-0"><a href="#cite_note-fda-1-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-FDA_12-0"><a href="#cite_note-FDA-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> In August 2008, four additional deaths from pancreatitis in users of exenatide were reported to the FDA; while no definite relationship had been established, the FDA was reportedly considering additional changes to the drug's labeling.<span class="mw-ref" id="cite_ref-nyt-2008_13-0"><a href="#cite_note-nyt-2008-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span>  Examination of the medical records of the millions of patients part of the United Healthcare Insurance plans did not show any greater rate of pancreatitis among Byetta users than among diabetic patients on other medications.  However, diabetics do have a slightly greater incidence of pancreatitis than do non-diabetics.<span class="mw-ref" id="cite_ref-pmid21577242_14-0"><a href="#cite_note-pmid21577242-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-pmid20833867_15-0"><a href="#cite_note-pmid20833867-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>

<p>It also may increase risk of mild sulfonylurea-induced hypoglycemia.<span class="mw-ref" id="cite_ref-pmid15504997_16-0"><a href="#cite_note-pmid15504997-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>

<p>Additionally, the FDA has raised concerns over the lack of data to determine if the long-acting once-weekly version of exenatide (but not the twice-daily form of exenatide) may increase  thyroid cancer risk.  This concern comes out of observing a very small but nevertheless increased risk of thyroid cancer in rodents that was observed for another drug (liraglutide) that is in the same class as exenatide.  The data available for exenatide showed less of a risk towards thyroid cancer than liraglutide, but to better quantify the risk the FDA has required Amylin to conduct additional rodent studies to better identify the thyroid issue.   The approved form of the once weekly exenatide [Bydureon] has a black box warning discussing the thyroid issue. Eli Lilly has reported they have not seen a link in humans, but that it cannot be ruled out. Eli Lilly has stated the drug causes an increase in thyroid problems in rats given high doses.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>

<p>In March 2013, the FDA issued a Drug Safety Communication announcing investigations into incretin mimetics due to findings by academic researchers.<span class="mw-ref" id="cite_ref-FDA,_2013_18-0"><a href="#cite_note-FDA,_2013-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span>  A few weeks later, the European Medicines Agency launched a similar investigation into GLP-1 agonists and DPP-4 inhibitors.<span class="mw-ref" id="cite_ref-EMA,_2013_19-0"><a href="#cite_note-EMA,_2013-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Exenatide binds to the intact human Glucagon-like peptide-1 receptor (GLP-1R) in a similar way to the human peptide glucagon-like peptide-1 (GLP-1); exenatide bears a 50% amino acid homology to GLP-1 and it has a longer half-life <i>in vivo</i>.<span class="mw-ref" id="cite_ref-pmid28283573_20-0"><a href="#cite_note-pmid28283573-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>

<p>Exenatide is believed to facilitate glucose control in at least five ways:</p>
<ol><li>Exenatide augments pancreas response<span class="mw-ref" id="cite_ref-pmid19196887_21-0"><a href="#cite_note-pmid19196887-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> (i.e. increases insulin secretion) in response to eating meals; the result is the release of a higher, more appropriate amount of insulin that helps lower the rise in blood sugar from eating. Once blood sugar levels decrease closer to normal values, the pancreas response to produce insulin is reduced; other drugs (like injectable insulin) are effective at lowering blood sugar, but can "overshoot" their target and cause blood sugar to become <i>too</i> low, resulting in the dangerous condition of hypoglycemia.</li>
<li>Exenatide also suppresses pancreatic release of <a href="Glucagon.htm" tppabs="https://ptable.com/wiki/compounds/A/Glucagon" title="Glucagon">glucagon</a> in response to eating, which helps stop the liver from overproducing sugar when it is unneeded, which prevents hyperglycemia (high blood sugar levels).</li>
<li>Exenatide helps slow down gastric emptying and thus decreases the rate at which meal-derived glucose appears in the bloodstream.</li>
<li>Exenatide has a subtle yet prolonged effect to reduce appetite, promote satiety via hypothalamic receptors (different receptors than for amylin). Most people using exenatide slowly lose weight, and generally the greatest weight loss is achieved by people who are the most overweight at the beginning of exenatide therapy. Clinical trials have demonstrated the weight reducing effect continues at the same rate through 2.25 years of continued use.  When separated into weight loss quartiles, the highest 25% experience substantial weight loss, and the lowest 25% experience no loss or small weight gain.</li>
<li>Exenatide reduces liver fat content. Fat accumulation in the liver or nonalcoholic fatty liver disease (NAFLD) is strongly related with several metabolic disorders, in particular low HDL cholesterol and high triglycerides, present in patients with type 2 diabetes. It became apparent that exenatide reduced liver fat in mice,<span class="mw-ref" id="cite_ref-pmid16374859_22-0"><a href="#cite_note-pmid16374859-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> rat<span class="mw-ref" id="cite_ref-Ali_ES_2016_23-0"><a href="#cite_note-Ali_ES_2016-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> and more recently in man.<span class="mw-ref" id="cite_ref-pmid16953843_24-0"><a href="#cite_note-pmid16953843-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></li></ol>

<p>In 2016 work published showing that it can reverse impaired calcium signalling in steatotic liver cells, which, in turn, might be associated with proper glucose control.<span class="mw-ref" id="cite_ref-Ali_ES_2016_23-1"><a href="#cite_note-Ali_ES_2016-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    
<p>Exenatide is a 39-amino-acid peptide; it is a synthetic version of <span class="new">Exendin-4</span>, a hormone found in the saliva of the Gila monster.<span class="mw-ref" id="cite_ref-Raufman1996_25-0"><a href="#cite_note-Raufman1996-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Exenatide was first isolated by John Eng in 1992 while working at the Veterans Administration Medical Center in the Bronx, New York.<span class="mw-ref" id="cite_ref-Raufman1996_25-1"><a href="#cite_note-Raufman1996-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> It is made by Amylin Pharmaceuticals and commercialized by AstraZeneca.</p>

<p>Exenatide was approved by the FDA on April 28, 2005 for people whose diabetes was not well-controlled on other oral medication.<span class="mw-ref" id="cite_ref-fda-approval_26-0"><a href="#cite_note-fda-approval-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    
<p>53 consolidated lawsuits against manufacturers of "GLP-1/DPP-4 products" were dismissed in 2015.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-AHFS2019-1"> <span id="mw-reference-text-cite_note-AHFS2019-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/exenatide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/exenatide.html'" tppabs="https://www.drugs.com/monograph/exenatide.html" class="external text external">"Exenatide Monograph for Professionals"</a>. <i>Drugs.com</i>. American Society of Health-System Pharmacists<span class="reference-accessdate">. Retrieved <span class="nowrap">22 March</span> 2019</span>.</cite></span></li><li id="cite_note-BNF76-2"> <span id="mw-reference-text-cite_note-BNF76-2" class="mw-reference-text"><cite class="citation book cs1"><i>British national formulary<span>&nbsp;</span>: BNF 76</i> (76 ed.). Pharmaceutical Press. 2018. pp.<span>&nbsp;</span>684–685. ISBN<span>&nbsp;</span><bdi>9780857113382</bdi>.</cite></span></li><li id="cite_note-Preg2019-3"> <span id="mw-reference-text-cite_note-Preg2019-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/exenatide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/exenatide.html'" tppabs="https://www.drugs.com/pregnancy/exenatide.html" class="external text external">"Exenatide Pregnancy and Breastfeeding Warnings"</a>. <i>Drugs.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">3 March</span> 2019</span>.</cite></span></li><li id="cite_note-NADAC2019-4"> <span id="mw-reference-text-cite_note-NADAC2019-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-02-27/s7c9-pfa6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-02-27/s7c9-pfa6'" tppabs="https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-02-27/s7c9-pfa6" class="external text external">"NADAC as of 2019-02-27"</a>. Centers for Medicare and Medicaid Services<span class="reference-accessdate">. Retrieved <span class="nowrap">3 March</span> 2019</span>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Top300Drugs.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Top300Drugs.aspx'" tppabs="https://clincalc.com/DrugStats/Top300Drugs.aspx" class="external text external">"The Top 300 of 2020"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Drugs/Exenatide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Drugs/Exenatide'" tppabs="https://clincalc.com/DrugStats/Drugs/Exenatide" class="external text external">"Exenatide - Drug Usage Statistics"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-UKByettalabel-7"> <span id="mw-reference-text-cite_note-UKByettalabel-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.medicines.org.uk/emc/product/8617/smpc  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medicines.org.uk/emc/product/8617/smpc'" tppabs="https://www.medicines.org.uk/emc/product/8617/smpc" class="external text external">"Byetta 10 micrograms solution for injection, prefilled pen - Summary of Product Characteristics"</a>. Electronic Medicines Compendium. 30 March 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">21 April</span> 2018</span>.</cite></span></li><li id="cite_note-UKBydureonlabel-8"> <span id="mw-reference-text-cite_note-UKBydureonlabel-8" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.medicines.org.uk/emc/product/3650/smpc  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medicines.org.uk/emc/product/3650/smpc'" tppabs="https://www.medicines.org.uk/emc/product/3650/smpc" class="external text external">"Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen - Summary of Product Characteristics"</a>. Electronic Medicines Compendium. 10 November 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">21 April</span> 2018</span>.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite id="CITEREFKimChoiWangLuo2017" class="citation journal cs1">Kim, DS; Choi, HI; Wang, Y; Luo, Y; Hoffer, BJ; Greig, NH (September 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680957  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680957'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680957" class="external text external">"A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway"</a>. <i>Cell Transplantation</i>. <b>26</b> (9): 1560–1571. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F0963689717721234  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F0963689717721234'" tppabs="https://doi.org/10.1177%2F0963689717721234" class="external text external">10.1177/0963689717721234</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680957  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680957'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680957" class="external text external">5680957</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29113464  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29113464'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29113464" class="external text external">29113464</a>.</cite></span></li><li id="cite_note-drugs.com-10"> <span id="mw-reference-text-cite_note-drugs.com-10" class="mw-reference-text"><a href="javascript:if(confirm('https://www.drugs.com/cons/byetta.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/cons/byetta.html'" tppabs="https://www.drugs.com/cons/byetta.html" class="external text external">Drugs.com Accessed September 6, 2008</a>.</span></li><li id="cite_note-fda-1-11"> <span id="mw-reference-text-cite_note-fda-1-11" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/Medwatch/SAFETY/2007/safety07.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Medwatch/SAFETY/2007/safety07.htm#Byetta'" tppabs="https://www.fda.gov/Medwatch/SAFETY/2007/safety07.htm#Byetta" class="external text external">2007 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements</a>, from the U.S. Food and Drug Administration. Accessed August 28, 2008.</span></li><li id="cite_note-FDA-12"> <span id="mw-reference-text-cite_note-FDA-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/Medwatch/SAFETY/2007/safety07.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Medwatch/SAFETY/2007/safety07.htm#Byetta'" tppabs="https://www.fda.gov/Medwatch/SAFETY/2007/safety07.htm#Byetta" class="external text external">"Byetta (exenatide) FDA warning"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2007-10-18</span></span>.</cite></span></li><li id="cite_note-nyt-2008-13"> <span id="mw-reference-text-cite_note-nyt-2008-13" class="mw-reference-text"><a href="javascript:if(confirm('https://www.nytimes.com/2008/08/27/business/27drug.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2008/08/27/business/27drug.html'" tppabs="https://www.nytimes.com/2008/08/27/business/27drug.html" class="external text external">Diabetes Drug Tied to New Deaths</a>. <i>The New York Times</i>. August 26, 2008; accessed August 28, 2008.</span></li><li id="cite_note-pmid21577242-14"> <span id="mw-reference-text-cite_note-pmid21577242-14" class="mw-reference-text"><cite id="CITEREFLaiMuoLiaoSung2011" class="citation journal cs1">Lai SW, Muo CH, Liao KF, Sung FC, Chen PC (September 2011). "Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan". <i>The American Journal of Gastroenterology</i>. <b>106</b> (9): 1697–704. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fajg.2011.155  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fajg.2011.155'" tppabs="https://doi.org/10.1038%2Fajg.2011.155" class="external text external">10.1038/ajg.2011.155</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21577242  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21577242'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21577242" class="external text external">21577242</a>.</cite></span></li><li id="cite_note-pmid20833867-15"> <span id="mw-reference-text-cite_note-pmid20833867-15" class="mw-reference-text"><cite id="CITEREFGonzalez-PerezSchliengerRodríguez2010" class="citation journal cs1">Gonzalez-Perez A, Schlienger RG, Rodríguez LA (December 2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992194'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992194" class="external text external">"Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study"</a>. <i>Diabetes Care</i>. <b>33</b> (12): 2580–5. doi:<a href="javascript:if(confirm('https://doi.org/10.2337%2Fdc10-0842  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2337%2Fdc10-0842'" tppabs="https://doi.org/10.2337%2Fdc10-0842" class="external text external">10.2337/dc10-0842</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992194'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992194" class="external text external">2992194</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20833867  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20833867'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20833867" class="external text external">20833867</a>.</cite></span></li><li id="cite_note-pmid15504997-16"> <span id="mw-reference-text-cite_note-pmid15504997-16" class="mw-reference-text"><cite id="CITEREFBuseHenryHanKim2004" class="citation journal cs1">Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group (November 2004). <a href="javascript:if(confirm('http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=15504997  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=15504997'" tppabs="http://care.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=15504997" class="external text external">"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes"</a>. <i>Diabetes Care</i>. <b>27</b> (11): 2628–35. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.2337%2Fdiacare.27.11.2628  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2337%2Fdiacare.27.11.2628'" tppabs="https://doi.org/10.2337%2Fdiacare.27.11.2628" class="external text external">10.2337/diacare.27.11.2628</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15504997  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15504997'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15504997" class="external text external">15504997</a>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite id="CITEREFSilverman2010" class="citation web cs1">Silverman E (2010-04-12). <a href="javascript:if(confirm('https://web.archive.org/web/20100606210411/http://pharmalot.com/2010/04/lillys-once-weekly-byetta-may-have-cancer-risk  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20100606210411/http://pharmalot.com/2010/04/lillys-once-weekly-byetta-may-have-cancer-risk'" tppabs="https://web.archive.org/web/20100606210411/http://pharmalot.com/2010/04/lillys-once-weekly-byetta-may-have-cancer-risk" class="external text external">"Lilly's Once-Weekly Byetta May Have Cancer Risk"</a>. <i>Pharmalot</i>. Archived from <a href="javascript:if(confirm('http://www.pharmalot.com/2010/04/lillys-once-weekly-byetta-may-have-cancer-risk  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pharmalot.com/2010/04/lillys-once-weekly-byetta-may-have-cancer-risk'" tppabs="http://www.pharmalot.com/2010/04/lillys-once-weekly-byetta-may-have-cancer-risk" class="external text external">the original</a> on 6 June 2010.</cite></span></li><li id="cite_note-FDA,_2013-18"> <span id="mw-reference-text-cite_note-FDA,_2013-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/Drugs/DrugSafety/ucm343187.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/DrugSafety/ucm343187.htm'" tppabs="https://www.fda.gov/Drugs/DrugSafety/ucm343187.htm" class="external text external">"FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes"</a>. <i>FDA</i>. U.S. Food and Drug Administration. March 3, 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-03-14</span></span>.</cite></span></li><li id="cite_note-EMA,_2013-19"> <span id="mw-reference-text-cite_note-EMA,_2013-19" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/03/news_detail_001753.jsp&,mid=WC0b01ac058004d5c1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/03/news_detail_001753.jsp&,mid=WC0b01ac058004d5c1'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/03/news_detail_001753.jsp&,mid=WC0b01ac058004d5c1" class="external text external">"European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes"</a>. <i>EMA</i>. European Medicines Agency Sciences Medicines Health. March 26, 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-03-26</span></span>.</cite></span></li><li id="cite_note-pmid28283573-20"> <span id="mw-reference-text-cite_note-pmid28283573-20" class="mw-reference-text"><cite id="CITEREFKooleReynoldsMobarecHick2017" class="citation journal cs1">Koole C, Reynolds CA, Mobarec JC, Hick C, Sexton PM, Sakmar TP (April 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409479  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409479'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409479" class="external text external">"Genetically encoded photocross-linkers determine the biological binding site of exendin-4 peptide in the N-terminal domain of the intact human glucagon-like peptide-1 receptor (GLP-1R)"</a>. <i>The Journal of Biological Chemistry</i>. <b>292</b> (17): 7131–7144. doi:<a href="javascript:if(confirm('https://doi.org/10.1074%2Fjbc.M117.779496  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1074%2Fjbc.M117.779496'" tppabs="https://doi.org/10.1074%2Fjbc.M117.779496" class="external text external">10.1074/jbc.M117.779496</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409479  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409479'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409479" class="external text external">5409479</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28283573  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28283573'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28283573" class="external text external">28283573</a>.</cite></span></li><li id="cite_note-pmid19196887-21"> <span id="mw-reference-text-cite_note-pmid19196887-21" class="mw-reference-text"><cite id="CITEREFBunckDiamantCornérEliasson2009" class="citation journal cs1">Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ (May 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671094  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671094'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671094" class="external text external">"One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial"</a>. <i>Diabetes Care</i>. <b>32</b> (5): 762–8. doi:<a href="javascript:if(confirm('https://doi.org/10.2337%2Fdc08-1797  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2337%2Fdc08-1797'" tppabs="https://doi.org/10.2337%2Fdc08-1797" class="external text external">10.2337/dc08-1797</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671094  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671094'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2671094" class="external text external">2671094</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19196887  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19196887'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19196887" class="external text external">19196887</a>.</cite></span></li><li id="cite_note-pmid16374859-22"> <span id="mw-reference-text-cite_note-pmid16374859-22" class="mw-reference-text"><cite id="CITEREFDingSaxenaLinGupta2006" class="citation journal cs1">Ding X, Saxena NK, Lin S, Gupta NA, Gupta N, Anania FA (January 2006). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925424  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925424'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925424" class="external text external">"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice"</a>. <i>Hepatology</i>. <b>43</b> (1): 173–81. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fhep.21006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fhep.21006'" tppabs="https://doi.org/10.1002%2Fhep.21006" class="external text external">10.1002/hep.21006</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925424  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925424'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925424" class="external text external">2925424</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16374859  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16374859'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16374859" class="external text external">16374859</a>.</cite></span></li><li id="cite_note-Ali_ES_2016-23"> <span id="mw-reference-text-cite_note-Ali_ES_2016-23" class="mw-reference-text"><cite id="CITEREFAliHuaWilsonTallis2016" class="citation journal cs1">Ali ES, Hua J, Wilson CH, Tallis GA, Zhou FH, Rychkov GY, Barritt GJ (September 2016). <a href="javascript:if(confirm('https://doi.org/10.1016/j.bbamcr.2016.05.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.bbamcr.2016.05.006'" tppabs="https://doi.org/10.1016/j.bbamcr.2016.05.006" class="external text external">"The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca(2+) signalling in steatotic hepatocytes"</a>. <i>Biochimica et Biophysica Acta (BBA) - Molecular Cell Research</i>. <b>1863</b> (9): 2135–46. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.bbamcr.2016.05.006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.bbamcr.2016.05.006'" tppabs="https://doi.org/10.1016%2Fj.bbamcr.2016.05.006" class="external text external">10.1016/j.bbamcr.2016.05.006</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27178543  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27178543'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27178543" class="external text external">27178543</a>.</cite></span></li><li id="cite_note-pmid16953843-24"> <span id="mw-reference-text-cite_note-pmid16953843-24" class="mw-reference-text"><cite id="CITEREFTushuizenBunckPouwelsvan_Waesberghe2006" class="citation journal cs1">Tushuizen ME, Bunck MC, Pouwels PJ, van Waesberghe JH, Diamant M, Heine RJ (October 2006). <a href="javascript:if(confirm('https://zenodo.org/record/896082  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://zenodo.org/record/896082'" tppabs="https://zenodo.org/record/896082" class="external text external">"Incretin mimetics as a novel therapeutic option for hepatic steatosis"</a>. <i>Liver International</i>. <b>26</b> (8): 1015–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1478-3231.2006.01315.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1478-3231.2006.01315.x'" tppabs="https://doi.org/10.1111%2Fj.1478-3231.2006.01315.x" class="external text external">10.1111/j.1478-3231.2006.01315.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16953843  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16953843'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16953843" class="external text external">16953843</a>.</cite></span></li><li id="cite_note-Raufman1996-25"> <span id="mw-reference-text-cite_note-Raufman1996-25" class="mw-reference-text"><cite id="CITEREFRaufman1996" class="citation journal cs1">Raufman JP (January 1996). "Bioactive peptides from lizard venoms". <i>Regulatory Peptides</i>. <b>61</b> (1): 1–18. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0167-0115%2896%2900135-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0167-0115%2896%2900135-8'" tppabs="https://doi.org/10.1016%2F0167-0115%2896%2900135-8" class="external text external">10.1016/0167-0115(96)00135-8</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8701022  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8701022'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8701022" class="external text external">8701022</a>.</cite></span></li><li id="cite_note-fda-approval-26"> <span id="mw-reference-text-cite_note-fda-approval-26" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/cder/rdmt/InternetNDA05.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/cder/rdmt/InternetNDA05.htm'" tppabs="https://www.fda.gov/cder/rdmt/InternetNDA05.htm" class="external text external">CDER Drug and Biologic Approvals for Calendar Year 2005</a>, from the U.S. Food and Drug Administration. Accessed August 28, 2008.</span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite id="CITEREFMoylan2015" class="citation news cs1">Moylan T (November 11, 2015). <a href="javascript:if(confirm('https://www.lexisnexis.com/legalnewsroom/litigation/b/litigation-blog/archive/2015/11/11/preemption-summary-judgment-granted-in-incretin-mimetic-multidistrict-litigation.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.lexisnexis.com/legalnewsroom/litigation/b/litigation-blog/archive/2015/11/11/preemption-summary-judgment-granted-in-incretin-mimetic-multidistrict-litigation.aspx'" tppabs="https://www.lexisnexis.com/legalnewsroom/litigation/b/litigation-blog/archive/2015/11/11/preemption-summary-judgment-granted-in-incretin-mimetic-multidistrict-litigation.aspx" class="external text external">"Preemption Summary Judgment Granted In Incretin-Mimetic Multidistrict Litigation"</a>. <i>Lexisnexis</i>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/exenatide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/exenatide'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/exenatide" class="external text external">"Exenatide"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li>
<li><a href="javascript:if(confirm('https://meshb.nlm.nih.gov/record/ui?name=exenatide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://meshb.nlm.nih.gov/record/ui?name=exenatide'" tppabs="https://meshb.nlm.nih.gov/record/ui?name=exenatide" class="external text external">exenatide</a><span> at the US National Library of Medicine </span>Medical Subject Headings<span> (MeSH)</span></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Oral_anti-diabetic_drugs,_insulins_and_insulin_analogs,_and_other_drugs_used_in_diabetes_(A10)" style="padding:3px"><table class="nowraplinks mw-collapsible expanded navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Oral_anti-diabetic_drugs,_insulins_and_insulin_analogs,_and_other_drugs_used_in_diabetes_(A10)" style="font-size:114%;margin:0 4em">Oral anti-diabetic drugs, <a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">insulins</a> and insulin analogs, and other drugs used in diabetes (A10)</div></th></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks mw-collapsible mw-collapsed navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Insulins/insulin_analogs" style="font-size:114%;margin:0 4em"><a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">Insulins</a>/insulin analogs</div></th></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><i>fast-acting</i></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Insulin aspart</li>
<li>Insulin glulisine</li>
<li>Insulin lispro</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><i>short-acting</i></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Regular insulin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><i>long-acting</i></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Insulin detemir</li>
<li>Insulin glargine (+lixisenatide)</li>
<li>NPH insulin</li>
<li>Lente insulin<sup>‡</sup></li>
<li>Ultralente insulin<sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><i>ultra-long-acting</i></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Insulin degludec (+insulin aspart, +liraglutide)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><i>inhalable</i></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Exubera<sup>‡</sup></li>
<li>Afreeza</li></ul>
</div></td></tr></tbody></table><div>
<div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table><div></div></td></tr><tr><td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks mw-collapsible mw-collapsed navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Non-insulins" style="font-size:114%;margin:0 4em">Non-insulins</div></th></tr><tr><td colspan="2" class="navbox-list navbox-odd" style="width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Insulin sensitizers</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Biguanides</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Buformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Buformin" title="Buformin">Buformin</a><sup>‡</sup></li>
<li><a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Metformin" title="Metformin">Metformin</a><sup>#</sup></li>
<li><a href="Phenformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenformin" title="Phenformin">Phenformin</a><sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Thiazolidinedione.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiazolidinedione" title="Thiazolidinedione">TZDs</a>/"glitazones" (PPAR)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Ciglitazone<sup>§</sup></li>
<li>Darglitazone<sup>§</sup></li>
<li>Englitazone<sup>§</sup></li>
<li>Lobeglitazone</li>
<li>Netoglitazone<sup>§</sup></li>
<li><a href="Pioglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Pioglitazone" title="Pioglitazone">Pioglitazone</a></li>
<li>Rivoglitazone<sup>†</sup></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Rosiglitazone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Rosiglitazone'" tppabs="https://ptable.com/wiki/compounds/A/Rosiglitazone" title="Rosiglitazone">Rosiglitazone</a></li>
<li><a href="Troglitazone.htm" tppabs="https://ptable.com/wiki/compounds/A/Troglitazone" title="Troglitazone">Troglitazone</a><sup>‡</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Dual PPAR agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Aleglitazar<sup>†</sup></li>
<li>Muraglitazar<sup>§</sup></li>
<li>Saroglitazar</li>
<li>Tesaglitazar<sup>§</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Secretagogues</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">K<sup>+</sup><sub>ATP</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Sulfonylureas</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>1st generation</i>: <a href="Acetohexamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Acetohexamide" title="Acetohexamide">Acetohexamide</a></li>
<li><a href="Carbutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Carbutamide" title="Carbutamide">Carbutamide</a></li>
<li><a href="Chlorpropamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpropamide" title="Chlorpropamide">Chlorpropamide</a></li>
<li><span class="new">Glycyclamide</span></li>
<li>Metahexamide</li>
<li><a href="Tolazamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolazamide" title="Tolazamide">Tolazamide</a></li>
<li><a href="Tolbutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolbutamide" title="Tolbutamide">Tolbutamide</a></li></ul>

<ul><li><i>2nd generation</i>: <a href="Glibenclamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Glibenclamide" title="Glibenclamide">Glibenclamide (glyburide)</a></li>
<li>Glibornuride</li>
<li>Glicaramide</li>
<li><a href="Gliclazide.htm" tppabs="https://ptable.com/wiki/compounds/A/Gliclazide" title="Gliclazide">Gliclazide</a><sup>#</sup></li>
<li><a href="Glimepiride.htm" tppabs="https://ptable.com/wiki/compounds/A/Glimepiride" title="Glimepiride">Glimepiride</a></li>
<li><a href="Glipizide.htm" tppabs="https://ptable.com/wiki/compounds/A/Glipizide" title="Glipizide">Glipizide</a></li>
<li><a href="Gliquidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gliquidone" title="Gliquidone">Gliquidone</a></li>
<li><a href="Glisoxepide.htm" tppabs="https://ptable.com/wiki/compounds/A/Glisoxepide" title="Glisoxepide">Glisoxepide</a></li>
<li>Glyclopyramide</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Meglitinides/"glinides"</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Mitiglinide.htm" tppabs="https://ptable.com/wiki/compounds/A/Mitiglinide" title="Mitiglinide">Mitiglinide</a></li>
<li><a href="Nateglinide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nateglinide" title="Nateglinide">Nateglinide</a></li>
<li><a href="Repaglinide.htm" tppabs="https://ptable.com/wiki/compounds/A/Repaglinide" title="Repaglinide">Repaglinide</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">GLP-1 receptor agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Albiglutide<sup>‡</sup></li>
<li>Dulaglutide</li>
<li><a href="Exenatide.htm" tppabs="https://ptable.com/wiki/compounds/A/Exenatide" title="Exenatide">Exenatide</a></li>
<li>Liraglutide</li>
<li>Lixisenatide</li>
<li>Semaglutide</li>
<li>Taspoglutide<sup>†</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">DPP-4 inhibitors/"gliptins"</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Alogliptin</li>
<li>Anagliptin</li>
<li>Evogliptin</li>
<li><span class="new">Garvagliptin</span></li>
<li>Gemigliptin</li>
<li>Gosogliptin</li>
<li>Linagliptin</li>
<li><span class="new">Melogliptin</span></li>
<li>Omarigliptin</li>
<li>Saxagliptin</li>
<li><a href="Sitagliptin.htm" tppabs="https://ptable.com/wiki/compounds/A/Sitagliptin" title="Sitagliptin">Sitagliptin</a></li>
<li>Teneligliptin</li>
<li>Trelagliptin</li>
<li>Vildagliptin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"> FFAR1 agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">Fasiglifam</span><sup>†</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Aldose reductase inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Epalrestat.htm" tppabs="https://ptable.com/wiki/compounds/A/Epalrestat" title="Epalrestat">Epalrestat</a></li>
<li>Fidarestat<sup>§</sup></li>
<li>Ranirestat<sup>†</sup></li>
<li><a href="Tolrestat.htm" tppabs="https://ptable.com/wiki/compounds/A/Tolrestat" title="Tolrestat">Tolrestat</a><sup>‡</sup></li>
<li>Zenarestat<sup>§</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Alpha-glucosidase inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Acarbose.htm" tppabs="https://ptable.com/wiki/compounds/A/Acarbose" title="Acarbose">Acarbose</a></li>
<li><a href="Miglitol.htm" tppabs="https://ptable.com/wiki/compounds/A/Miglitol" title="Miglitol">Miglitol</a></li>
<li><a href="Voglibose.htm" tppabs="https://ptable.com/wiki/compounds/A/Voglibose" title="Voglibose">Voglibose</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Amylin analog</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Pramlintide.htm" tppabs="https://ptable.com/wiki/compounds/A/Pramlintide" title="Pramlintide">Pramlintide</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">SGLT2 inhibitors/"gliflozins"</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Canagliflozin</li>
<li>Dapagliflozin</li>
<li>Empagliflozin</li>
<li>Ertugliflozin</li>
<li>Ipragliflozin</li>
<li>Remogliflozin<sup>§</sup></li>
<li>Sergliflozin<sup>§</sup></li>
<li>Tofogliflozin<sup>†</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Benfluorex<sup>‡</sup></li>
<li><a href="Bromocriptine.htm" tppabs="https://ptable.com/wiki/compounds/A/Bromocriptine" title="Bromocriptine">Bromocriptine</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Combinations</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><td colspan="2" class="navbox-list navbox-even" style="width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Alogliptin/metformin</li>
<li>Canagliflozin/metformin</li>
<li>Dapagliflozin/metformin</li>
<li>Dapagliflozin/saxagliptin</li>
<li>Dapagliflozin/saxagliptin/metformin</li>
<li>Empagliflozin/metformin</li>
<li><span class="new">Gemigliptin/rosuvastatin</span></li>
<li>Glibenclamide (glyburide)/metformin</li>
<li><span class="new">Glimepiride/rosiglitazone</span></li>
<li><span class="new">Linagliptin/empagliflozin</span></li>
<li><a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Linagliptin/metformin" title="Linagliptin/metformin" class="mw-redirect">Linagliptin/metformin</a></li>
<li><span class="new">Metformin/acarbose</span></li>
<li>Metformin/ertugliflozin</li>
<li><span class="new">Metformin/evogliptin</span></li>
<li><span class="new">Metformin/gemigliptin</span></li>
<li><span class="new">Metformin/repaglinide</span></li>
<li><span class="new">Metformin/sulfonylureas</span></li>
<li><span class="new">Phenformin/sulfonylureas</span></li>
<li>Pioglitazone/alogliptin</li>
<li>Pioglitazone/glimepiride</li>
<li>Pioglitazone/metformin</li>
<li><span class="new">Pioglitazone/sitagliptin</span></li>
<li><a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Rosiglitazone/metformin" title="Rosiglitazone/metformin" class="mw-redirect">Rosiglitazone/metformin</a></li>
<li><a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Saxagliptin/metformin" title="Saxagliptin/metformin" class="mw-redirect">Saxagliptin/metformin</a></li>
<li><span class="new">Sitagliptin/ertugliflozin</span></li>
<li>Sitagliptin/metformin</li>
<li>Sitagliptin/simvastatin</li>
<li>Vildagliptin/metformin</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table><div>
<div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table><div></div></td></tr></tbody></table></div><span>
</span>
<span>
</span><div role="navigation" class="navbox" aria-labelledby="Signaling_peptide/protein_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Signaling_peptide/protein_receptor_modulators" style="font-size:114%;margin:0 4em">Signaling peptide/protein receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Adiponectin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">AdipoR<sub>1</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <i>Peptide:</i> Adiponectin</li>
<li><span class="new">ADP-355</span></li>
<li><span class="new">ADP-399</span>; <i>Non-peptide:</i> AdipoRon</li>
<li>(–)-Arctigenin</li>
<li>Arctiin</li>
<li><a href="Gramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Gramine" title="Gramine">Gramine</a></li>
<li><a href="Matairesinol.htm" tppabs="https://ptable.com/wiki/compounds/A/Matairesinol" title="Matairesinol">Matairesinol</a></li></ul>

<ul><li><i>Antagonists:</i> <i>Peptide:</i> <span class="new">ADP-400</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">AdipoR<sub>2</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <i>Peptide:</i> Adiponectin</li>
<li><span class="new">ADP-355</span></li>
<li><span class="new">ADP-399</span>; <i>Non-peptide:</i> AdipoRon</li>
<li>Deoxyschizandrin</li>
<li><a href="Parthenolide.htm" tppabs="https://ptable.com/wiki/compounds/A/Parthenolide" title="Parthenolide">Parthenolide</a></li>
<li><span class="new">Syringing</span></li>
<li>Taxifoliol</li></ul>

<ul><li><i>Antagonists:</i> <i>Peptide:</i> <span class="new">ADP-400</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Angiotensin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Bradykinin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Bradykinin.htm" tppabs="https://ptable.com/wiki/compounds/A/Bradykinin" title="Bradykinin">Bradykinin</a></li>
<li>Kallidin</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">FR-173657</span></li>
<li><a href="Icatibant.htm" tppabs="https://ptable.com/wiki/compounds/A/Icatibant" title="Icatibant">Icatibant</a></li>
<li>LF22-0542</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CGRP</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Amylin</li>
<li>CGRP</li>
<li><a href="Pramlintide.htm" tppabs="https://ptable.com/wiki/compounds/A/Pramlintide" title="Pramlintide">Pramlintide</a></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">Atogepant</span></li>
<li><span class="new">BI 44370 TA</span></li>
<li><span class="new">CGRP (8-37)</span></li>
<li><span class="new">MK-3207</span></li>
<li>Olcegepant</li>
<li>Rimegepant</li>
<li><span class="new">SB-268262</span></li>
<li><a href="Telcagepant.htm" tppabs="https://ptable.com/wiki/compounds/A/Telcagepant" title="Telcagepant">Telcagepant</a></li>
<li>Ubrogepant</li></ul>

<ul><li><i>Antibodies:</i> Eptinezumab</li>
<li>Erenumab</li>
<li>Fremanezumab</li>
<li>Galcanezumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Cholecystokinin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CCK<sub>A</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Cholecystokinin</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">Amiglumide</span></li>
<li>Asperlicin</li>
<li>Devazepide</li>
<li>Dexloxiglumide</li>
<li><span class="new">Lintitript</span></li>
<li>Lorglumide</li>
<li><span class="new">Loxiglumide</span></li>
<li><span class="new">Pranazepide</span></li>
<li>Proglumide</li>
<li><span class="new">Tarazepide</span></li>
<li><span class="new">Tomoglumide</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CCK<sub>B</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Cholecystokinin</li>
<li>CCK-4</li>
<li>Gastrin</li>
<li><a href="Pentagastrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Pentagastrin" title="Pentagastrin">Pentagastrin (CCK-5)</a></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">Ceclazepide</span></li>
<li>CI-988 (PD-134308)</li>
<li><span class="new">Itriglumide</span></li>
<li><span class="new">L-365,360</span></li>
<li><span class="new">Netazepide</span></li>
<li>Proglumide</li>
<li><span class="new">Spiroglumide</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Antagonists:</i> <span class="new">Nastorazepide</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CRH</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CRF<sub>1</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Cortagine</span></li>
<li>Corticorelin</li>
<li>Corticotropin-releasing hormone</li>
<li>Sauvagine</li>
<li><span class="new">Stressin I</span></li>
<li>Urocortin</li></ul>

<ul><li><i>Antagonists:</i> Antalarmin</li>
<li>Astressin-B</li>
<li>CP-154,526</li>
<li>Emicerfont</li>
<li>Hypericin</li>
<li><span class="new">LWH-234</span></li>
<li><span class="new">NBI-27914</span></li>
<li><span class="new">NBI-74788</span></li>
<li>Pexacerfont</li>
<li><span class="new">R-121919</span></li>
<li><span class="new">TS-041</span></li>
<li>Verucerfont</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CRF<sub>2</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Corticorelin</li>
<li>Corticotropin-releasing hormone</li>
<li>Sauvagine</li>
<li>Urocortin</li></ul>

<ul><li><i>Antagonists:</i> Astressin-B</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Cytokine</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">See here instead.</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Endothelin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Endothelin 1</li>
<li>Endothelin 2</li>
<li>Endothelin 3</li>
<li><span class="new">IRL-1620</span></li>
<li>Sarafotoxin</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">A-192621</span></li>
<li><span class="new">ACT-132577</span></li>
<li>Ambrisentan</li>
<li><span class="new">Aprocitentan</span></li>
<li>Atrasentan</li>
<li><span class="new">Avosentan</span></li>
<li><a href="Bosentan.htm" tppabs="https://ptable.com/wiki/compounds/A/Bosentan" title="Bosentan">Bosentan</a></li>
<li>BQ-123</li>
<li>BQ-788</li>
<li><span class="new">Clazosentan</span></li>
<li>Darusentan</li>
<li><span class="new">Edonentan</span></li>
<li><span class="new">Enrasentan</span></li>
<li><span class="new">Fandosentan</span></li>
<li><span class="new">Feloprentan</span></li>
<li>Macitentan</li>
<li><span class="new">Nebentan</span></li>
<li>Sitaxentan</li>
<li><span class="new">Sparsentan</span></li>
<li>Tezosentan</li>
<li>Zibotentan</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Galanin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GAL<sub>1</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Galanin</li>
<li><span class="new">Galanin (1-15)</span></li>
<li>Galanin-like peptide</li>
<li>Galmic</li>
<li>Galnon</li>
<li><span class="new">NAX 810-2</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">C7</span></li>
<li><span class="new">Dithiepine-1,1,4,4-tetroxide</span></li>
<li><span class="new">Galantide (M15)</span></li>
<li><span class="new">M32</span></li>
<li><span class="new">M35</span></li>
<li><span class="new">M40</span></li>
<li><span class="new">SCH-202596</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GAL<sub>2</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Galanin</li>
<li><span class="new">Galanin (1-15)</span></li>
<li><span class="new">Galanin (2-11)</span></li>
<li>Galanin-like peptide</li>
<li>Galmic</li>
<li>Galnon</li>
<li><span class="new">J18</span></li>
<li><span class="new">NAX 810-2</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">C7</span></li>
<li><span class="new">Galantide (M15)</span></li>
<li><span class="new">M32</span></li>
<li><span class="new">M35</span></li>
<li><span class="new">M40</span></li>
<li><span class="new">M871</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GAL<sub>3</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Galanin</li>
<li><span class="new">Galanin (1-15)</span></li>
<li>Galmic</li>
<li>Galnon</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">C7</span></li>
<li><span class="new">Galantide (M15)</span></li>
<li><span class="new">GalR3ant</span></li>
<li>HT-2157</li>
<li><span class="new">M32</span></li>
<li><span class="new">M35</span></li>
<li><span class="new">M40</span></li>
<li>SNAP-37889</li>
<li><span class="new">SNAP-398299</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Ghrelin/GHS</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GH</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GHRH</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GLP</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GLP-1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Albiglutide</li>
<li><span class="new">Beinaglutide</span></li>
<li>Dulaglutide</li>
<li><span class="new">Efpeglenatide</span></li>
<li><a href="Exenatide.htm" tppabs="https://ptable.com/wiki/compounds/A/Exenatide" title="Exenatide">Exenatide</a></li>
<li>GLP-1</li>
<li><span class="new">Langlenatide</span></li>
<li>Liraglutide</li>
<li>Lixisenatide</li>
<li>Oxyntomodulin</li>
<li><span class="new">Pegapamodutide</span></li>
<li>Semaglutide</li>
<li>Taspoglutide</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GLP-2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Apraglutide</span></li>
<li><span class="new">Elsiglutide</span></li>
<li><span class="new">Glepaglutide</span></li>
<li>GLP-2</li>
<li>Teduglutide</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Propeptides:</i> Preproglucagon</li>
<li>Proglucagon</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Glucagon</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Dasiglucagon</span></li>
<li><a href="Glucagon.htm" tppabs="https://ptable.com/wiki/compounds/A/Glucagon" title="Glucagon">Glucagon</a></li>
<li>Oxyntomodulin</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">Adomeglivant</span></li>
<li><span class="new">L-168,049</span></li>
<li><span class="new">LGD-6972</span></li></ul>

<ul><li><i>Propeptides:</i> Preproglucagon</li>
<li>Proglucagon</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GnRH</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Gonadotropin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Growth factor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">See here instead.</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Insulin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Chaetochromin (4548-G05)</li>
<li>Insulin-like growth factor 1</li>
<li>Insulin-like growth factor 2</li>
<li><a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">Insulin</a></li>
<li>Insulin aspart</li>
<li>Insulin degludec</li>
<li>Insulin detemir</li>
<li>Insulin glargine</li>
<li>Insulin glulisine</li>
<li>Insulin lispro</li>
<li><a href="Mecasermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mecasermin" title="Mecasermin">Mecasermin</a></li>
<li>Mecasermin rinfabate</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">BMS-754807</span></li>
<li><span class="new">S661</span></li>
<li><span class="new">S961</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> Linsitinib</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Kisspeptin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Kisspeptin</li>
<li><span class="new">Kisspeptin-10</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">Kisspeptin-234</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Leptin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Leptin</li>
<li>Metreleptin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">MCH</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">MCH<sub>1</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Melanin-concentrating hormone</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ATC-0065</span></li>
<li>ATC-0175</li>
<li>GW-803430</li>
<li>NGD-4715</li>
<li>SNAP-7941</li>
<li>SNAP-94847</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">MCH<sub>2</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Melanin-concentrating hormone</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Melanocortin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Neuropeptide FF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Neuropeptide AF</span></li>
<li>Neuropeptide FF</li>
<li><span class="new">Neuropeptide SF (RFRP-1)</span></li>
<li><span class="new">Neuropeptide VF (RFRP-3)</span></li></ul>

<ul><li><i>Antagonists:</i> BIBP-3226</li>
<li><span class="new">RF9</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Neuropeptide S</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neuropeptide S</li></ul>

<ul><li><i>Antagonists:</i> ML-154</li>
<li>SHA-68</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="Neuropeptide_Y_receptor.htm" tppabs="https://ptable.com/wiki/compounds/A/Neuropeptide_Y_receptor" title="Neuropeptide Y receptor">Neuropeptide Y</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Y<sub>1</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neuropeptide Y</li>
<li>Peptide YY</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">BIBO-3304</span></li>
<li>BIBP-3226</li>
<li><span class="new">BVD-10</span></li>
<li><span class="new">GR-231118</span></li>
<li><span class="new">PD-160170</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Y<sub>2</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">2-Thiouridine 5'-triphosphate</span></li>
<li>Neuropeptide Y</li>
<li><span class="new">Neuropeptide Y (13-36)</span></li>
<li>Peptide YY</li>
<li><span class="new">Peptide YY (3-36)</span></li></ul>

<ul><li><i>Antagonists:</i> BIIE-0246</li>
<li><span class="new">JNJ-5207787</span></li>
<li><span class="new">SF-11</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Y<sub>4</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">GR-231118</span></li>
<li>Neuropeptide Y</li>
<li>Pancreatic polypeptide</li>
<li>Peptide YY</li></ul>

<ul><li><i>Antagonists:</i> UR-AK49</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Y<sub>5</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">BWX-46</span></li>
<li>Neuropeptide Y</li>
<li>Peptide YY</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">CGP-71683</span></li>
<li><span class="new">FMS-586</span></li>
<li><span class="new">L-152,804</span></li>
<li>Lu AA-33810</li>
<li><span class="new">MK-0557</span></li>
<li><span class="new">NTNCB</span></li>
<li>Velneperit (S-2367)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Neurotensin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">NTS<sub>1</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neurotensin</li>
<li>Neuromedin N</li></ul>

<ul><li><i>Antagonists:</i> Meclinertant</li>
<li>SR-142948</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">NTS<sub>2</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neurotensin</li></ul>

<ul><li><i>Antagonists:</i> <a href="Levocabastine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levocabastine" title="Levocabastine">Levocabastine</a></li>
<li>SR-142948</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Opioid</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">See here instead.</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Orexin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">OX<sub>1</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Orexin (A, B)</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ACT-335827</span></li>
<li><span class="new">ACT-462206</span></li>
<li>Almorexant</li>
<li>Filorexant</li>
<li>Lemborexant</li>
<li>Nemorexant</li>
<li><span class="new">RTIOX-276</span></li>
<li>SB-334867</li>
<li>SB-408124</li>
<li>SB-649868</li>
<li>Suvorexant</li>
<li><span class="new">TCS-1102</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">OX<sub>2</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Orexin (A, B)</li>
<li><span class="new">SB-668875</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ACT-335827</span></li>
<li><span class="new">ACT-462206</span></li>
<li>Almorexant</li>
<li>EMPA</li>
<li>Filorexant</li>
<li><span class="new">JNJ-10397049</span></li>
<li>Lemborexant</li>
<li><span class="new">MK-1064</span></li>
<li>SB-649868</li>
<li>Seltorexant</li>
<li>Suvorexant</li>
<li><span class="new">TCS-1102</span></li>
<li>TCS-OX2-29</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Oxytocin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Prolactin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Growth_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Growth_hormone" title="Growth hormone">Growth hormone</a></li>
<li>Human placental lactogen</li>
<li>Placental growth hormone (growth hormone variant)</li>
<li>Prolactin</li>
<li><span class="new">S179D-hPRL</span></li>
<li><a href="Growth_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Somatotropin" title="Somatotropin" class="mw-redirect">Somatotropin</a></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">Δ1–9-G129R-hPRL</span></li>
<li><span class="new">Δ1–14-G129R-hPRL</span></li>
<li><span class="new">G120K-hGH</span></li>
<li><span class="new">G129R-hPRL</span></li></ul>

<ul><li><i>Prolactin modulators:</i> <i>Prolactin inhibitors:</i> D<sub>2</sub> receptor agonists (e.g., <a href="Bromocriptine.htm" tppabs="https://ptable.com/wiki/compounds/A/Bromocriptine" title="Bromocriptine">bromocriptine</a>, <a href="Cabergoline.htm" tppabs="https://ptable.com/wiki/compounds/A/Cabergoline" title="Cabergoline">cabergoline</a>); <i>Prolactin releasers:</i> D<sub>2</sub> receptor antagonists (e.g., <a href="Domperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Domperidone" title="Domperidone">domperidone</a>, <a href="Metoclopramide.htm" tppabs="https://ptable.com/wiki/compounds/A/Metoclopramide" title="Metoclopramide">metoclopramide</a>, <a href="Risperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Risperidone" title="Risperidone">risperidone</a>)</li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a> (e.g., <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a>)</li>
<li>Progestogens (e.g., <a href="Progesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Progesterone" title="Progesterone">progesterone</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">PTH</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Abaloparatide</li>
<li>Parathyroid hormone</li>
<li>Parathyroid hormone-related protein (PTHrP)</li>
<li><span class="new">Semparatide</span></li>
<li><a href="Teriparatide.htm" tppabs="https://ptable.com/wiki/compounds/A/Teriparatide" title="Teriparatide">Teriparatide</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Relaxin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Insulin-like factor 3</li>
<li>Relaxin (<span class="new">1</span>, <span class="new">2</span>, 3)</li>
<li>Serelaxin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Somatostatin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Tachykinin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TRH</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Azetirelin</span></li>
<li>Fertirelin</li>
<li><span class="new">Montirelin</span></li>
<li><span class="new">Orotirelin</span></li>
<li><span class="new">Posatirelin</span></li>
<li><a href="Thyrotropin-releasing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Protirelin" title="Protirelin" class="mw-redirect">Protirelin</a></li>
<li><span class="new">Rovatirelin</span></li>
<li>Taltirelin</li>
<li><a href="Thyrotropin-releasing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Thyrotropin-releasing_hormone" title="Thyrotropin-releasing hormone">TRH (TRF)</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TSH</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Thyrotropin alfa</li>
<li><a href="Thyroid-stimulating_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Thyroid-stimulating_hormone" title="Thyroid-stimulating hormone">TSH (thyrotropin)</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Vasopressin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">VIP/PACAP</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">VIPR<sub>1</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <i>Peptide:</i> <span class="new">Bay 55-9837</span></li>
<li><span class="new">LBT-3393</span></li>
<li>PACAP</li>
<li>VIP</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">VIPR<sub>2</sub></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <i>Peptide:</i> LBT-3627</li>
<li>PACAP</li>
<li>VIP</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">PAC<sub>1</sub></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> PACAP</li>
<li><span class="new">PACAP (1-27)</span></li>
<li><span class="new">PACAP (1-38)</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">PACAP (6-38)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">PHI</span></li>
<li><span class="new">PHM</span></li>
<li><span class="new">PHV</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Endogenous:</i> Adrenomedullin</li>
<li>Apelin</li>
<li>Asprosin</li>
<li>Bombesin</li>
<li>Calcitonin</li>
<li><a href="Carnosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Carnosine" title="Carnosine">Carnosine</a></li>
<li>CART</li>
<li>CLIP</li>
<li>DSIP</li>
<li>Enteroglucagon</li>
<li>Formyl peptide</li>
<li>GALP</li>
<li>GIP</li>
<li>GRP</li>
<li>Integrin ligands (collagens, fibrinogen, fibronectin, laminins, ICAM-1, ICAM-2, osteopontin, VCAM-1, vitronectin)</li>
<li>Kininogens</li>
<li>Motilin</li>
<li>Natriuretic peptides (ANP, BNP, CNP, urodilatin)</li>
<li>Nesfatin-1</li>
<li>Neuromedin B</li>
<li>Neuromedin N</li>
<li>Neuromedin S</li>
<li>Neuromedin U</li>
<li>Obestatin</li>
<li>Osteocalcin</li>
<li>Resistin</li>
<li><a href="Secretin.htm" tppabs="https://ptable.com/wiki/compounds/A/Secretin" title="Secretin">Secretin</a></li>
<li>Thymopoietin</li>
<li>Thymosins</li>
<li>Thymulin</li>
<li>Urotensin-II</li>
<li>VGF</li></ul>

<ul><li><i>Exogenous:</i> Lifitegrast (LFA-1 antagonist)</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd></dl>
</div></td></tr></tbody></table></div><span>
</span>






<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-07-31" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Exenatide&oldid=970536160  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Exenatide&oldid=970536160'" tppabs="https://en.wikipedia.org/wiki/?title=Exenatide&oldid=970536160">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>